Search
for
Sort by
Research 30 of 557
- A97 TACROLIMUS-ASSOCIATED HEMOLYTIC UREMIC SYNDROME IN A PEDIATRIC LIVER TRANSPLANT RECIPIENT
- Single Best Answers
- Section 2: Single Best Answers Questions 51–120
- Rheumatologic Manifestations of Pregnancy
- Issue Information ‐ TOC
- TONGUE, RED
- Toxic and Metabolic Disorders of the Nervous System
- Minoxidil therapy in children with severe hypertension
- Contact Allergic Dermatitis to Quinine in an Anti-hair Loss Lotion
- Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management
- Diet in dermatology: Revisited
- General Dermatology
- The Clinical Presentation of Systemic Lupus Erythematosus
- A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus
- The spectrum of nephrocutaneous diseases and associations
- Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk
- The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
- SLE and Serum Complement: Causative, Concomitant or Coincidental?
- Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study
- Platelet-Therapeutics to Improve Tissue Regeneration and Wound Healing—Physiological Background and Methods of Preparation
- Oral cyclosporin does not arrest progression of androgenetic alopecia
- Hypertension in Children and Adolescents
- Metabolic disease with autoimmune phenomena: 2 cases of SLE-like disease in young children diagnosed with lysinuric protein intolerance
- Does Complement Have a Role in the Pathogenesis of Alopecia Areata?
- Antioxidant Activities of Natural Polysaccharides and Their Derivatives for Biomedical and Medicinal Applications
- Knowledge Mapping of Drug Repositioning’s Theme and Development
- Childhood‐onset systemic lupus erythematosus with trisomy X and the increased risk for bone complications: a case report
- Direct Vasodilators and Sympatholytic Agents
- Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
- Combined C3b and Factor B Autoantibodies and MPGN Type II